Brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to post $1.69 earnings per share for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for Gilead Sciences’ earnings. The highest EPS estimate is $2.11 and the lowest is $1.29. Gilead Sciences reported earnings per share of $2.70 in the same quarter last year, which suggests a negative year-over-year growth rate of 37.4%. The company is expected to issue its next quarterly earnings results after the market closes on Tuesday, February 6th.

According to Zacks, analysts expect that Gilead Sciences will report full-year earnings of $8.71 per share for the current financial year, with EPS estimates ranging from $8.36 to $9.17. For the next fiscal year, analysts expect that the business will report earnings of $6.85 per share, with EPS estimates ranging from $6.03 to $8.04. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.75 EPS.

GILD has been the subject of several recent research reports. BMO Capital Markets reissued a “hold” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Friday, October 20th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Morgan Stanley reissued an “equal weight” rating and issued a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Bank of America lowered their price target on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, October 4th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $85.61.

Gilead Sciences (NASDAQ:GILD) traded up $1.14 during trading on Tuesday, reaching $80.16. 7,818,732 shares of the company’s stock traded hands, compared to its average volume of 8,065,822. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The company has a market capitalization of $104,500.00, a P/E ratio of 9.12, a PEG ratio of -1.68 and a beta of 1.13. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 461,666 shares of company stock worth $34,072,567. Corporate insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of GILD. Capital Asset Advisory Services LLC bought a new position in shares of Gilead Sciences in the second quarter worth approximately $875,000. Factory Mutual Insurance Co. lifted its stake in shares of Gilead Sciences by 4.6% in the second quarter. Factory Mutual Insurance Co. now owns 586,000 shares of the biopharmaceutical company’s stock worth $41,477,000 after buying an additional 26,000 shares in the last quarter. Prentiss Smith & Co. Inc. bought a new position in shares of Gilead Sciences in the second quarter worth approximately $497,000. Hellman Jordan Management Co. Inc. MA bought a new position in shares of Gilead Sciences in the second quarter worth approximately $839,000. Finally, First American Bank lifted its stake in shares of Gilead Sciences by 19.9% in the second quarter. First American Bank now owns 74,301 shares of the biopharmaceutical company’s stock worth $5,259,000 after buying an additional 12,352 shares in the last quarter. Hedge funds and other institutional investors own 75.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Gilead Sciences, Inc. (GILD) to Announce $1.69 Earnings Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/16/zacks-analysts-anticipate-gilead-sciences-inc-gild-to-announce-1-69-earnings-per-share.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.